Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The sites can include the upper arm, thigh, or abdomen
Accessed July 23, 2025.
This was the key outcome they were shooting for
10.1 PBM-Owned Biosimilars: A New Competitive Threat The Humira and Stelara biosimilar experiences established a precedent that is likely to expand: major PBMs are now willing to launch private-label biosimilar products through affiliated subsidiaries, then use their formulary and network position to drive covered lives toward their own products and away from both reference biologics and independently manufactured biosimilars
Side effects are rare and typically mild occasional lightheadedness, nausea, or injection site discomfort
US$ 29.09
US$ 24.77
US$ 21.00
US$ 25.39
US$ 27.60
US$ 19.99
US$ 26.42
US$ 23.82
